Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Accumulated Expenses (2018 - 2025)

Historic Accumulated Expenses for Abvc Biopharma (ABVC) over the last 12 years, with Q3 2025 value amounting to $154780.0.

  • Abvc Biopharma's Accumulated Expenses fell 4136.5% to $154780.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $154780.0, marking a year-over-year decrease of 4136.5%. This contributed to the annual value of $126106.0 for FY2024, which is 22485.64% up from last year.
  • According to the latest figures from Q3 2025, Abvc Biopharma's Accumulated Expenses is $154780.0, which was down 4136.5% from $160914.0 recorded in Q2 2025.
  • In the past 5 years, Abvc Biopharma's Accumulated Expenses ranged from a high of $3.6 million in Q3 2023 and a low of $38819.0 during Q4 2023
  • In the last 5 years, Abvc Biopharma's Accumulated Expenses had a median value of $1.2 million in 2024 and averaged $1.4 million.
  • As far as peak fluctuations go, Abvc Biopharma's Accumulated Expenses crashed by 9866.58% in 2023, and later soared by 22485.64% in 2024.
  • Abvc Biopharma's Accumulated Expenses (Quarter) stood at $1.3 million in 2021, then soared by 123.68% to $2.9 million in 2022, then tumbled by 98.67% to $38819.0 in 2023, then surged by 224.86% to $126106.0 in 2024, then rose by 22.74% to $154780.0 in 2025.
  • Its Accumulated Expenses stands at $154780.0 for Q3 2025, versus $160914.0 for Q2 2025 and $140252.0 for Q1 2025.